Search Results - irwin+bernstein

3 Results

Sort By:

Method of adoptive T cell therapy utilizing notch signaling to enhance efficacy

Notch Activation to Improve Persistence and Efficacy of T Cell Therapies Method of using Notch ligands during culturing to improve the persistence and efficacy of CAR T cell therapies. While CAR T-based cell therapies are promising, the persistence, proliferation, and efficacy of those engineered T cell therapies need to be improved. Additionally,...

Published: 10/14/2024 | Updated: 3/10/2024 | Inventor(s): Irwin Bernstein, Stanley Riddell, Margot Pont

Keywords(s): Immuno Oncology, Target

Category(s): Therapeutic

Notch ligand Delta 4 and anti-CD33 Bispecific Reagent for Treating Cancer and Other Diseases

Novel Bispecific to Alter the Immunosuppressive Tumor Microenvironment Compositions and methods of treatment of a novel bispecific reagent that targets Notch ligand to tumor sites. The tumor microenvironment (TME) consists of the complex ecosystem where cancerous cells reside and interact with their non-malignant neighbors, including immunosuppressive...

Published: 10/14/2024 | Updated: 10/4/2021 | Inventor(s): Irwin Bernstein, Vincent Luca, Kenan Garcia

Keywords(s): Hybridoma / Antibody, Immuno Oncology

Category(s): Therapeutic

Methods to Expand and Manipulate Hematopoietic Stem and Progenitor Cells

Methods to expand and manipulate hematopoietic stem and progenitor cells Culture strategies for cost effective, ex vivo expansion of hematopoietic stem and progenitor cells (HSPCs) with enhanced in vivo repopulating ability. HSPCs can be used to treat over 70 types of diseases including a variety of hematological disorders through transplantation...

Published: 10/14/2024 | Updated: 12/19/2019 | Inventor(s): Irwin Bernstein, Chengcheng Zhang, Mi Deng, Zhigang Lu, Junke Zheng

Keywords(s): HSC Therapy

Category(s): Cell Therapy